Oral contraceptives and the risk of hereditary ovarian cancer

New England Journal of Medicine

Volumn 339, Issue 7, 1998, Pages 424-428

  Narod, Steven A ^a,k   Risch, Harvey ^b   Moslehi, Roxana ^c   Dørum, Anne ^d   Neuhausen, Susan ^e   Olsson, Hakan ^f   Provencher, Diane ^g   Radice, Paolo ^h   Evans, Gareth ⁱ   Bishop, Susan ^a   Brunet, Jean Sébastien ^a   Ponder, Bruce A J ^j   Klijn, Jan G M ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f LUND UNIVERSITY   (Sweden)

^g NOTRE DAME HOSPITAL   (Canada)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ ST MARY S HOSPITAL   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k WOMEN S COLLEGE HOSPITAL   (Canada)

^l ERASMUS MC CANCER INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRCA2 PROTEIN; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR FAMILY; ODDS RATIO; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0032514413     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808133390702     Document Type: Article

References (11)

1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
3. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-71.
4. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1997;277:997-1003.
5. Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-203.
6. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 1991;49:61-5.
7. Hogervorst FB, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
8. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179-83.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
10. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol 1994;139-670-83.
11. Ursin G, Henderson BE, Haile RW, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997;57:3678-81.